Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease

被引:32
作者
Kushleika, J
Checkoway, H
Woods, JS
Moon, JD
SmithWellar, T
Franklin, GM
Swanson, PD
机构
[1] UNIV WASHINGTON,DEPT ENVIRONM HLTH,SEATTLE,WA 98195
[2] UNIV WASHINGTON,DEPT NEUROL,SEATTLE,WA 98195
[3] CHONNAM NATL UNIV,SCH MED,DEPT PREVENT MED,KWANGJU,SOUTH KOREA
关键词
D O I
10.1002/ana.410390315
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Superoxide dismutases (SODs) are metalloenzymes that detoxify superoxide radicals, and occur in cytosolic (Cu,Zn-SOD) and mitochondrial (Mn-SOD) forms in multiple tissues, including brain. A neuroprotective effect against oxide stressor exposures may be provided by SOD, although excessive enzyme activity can produce cell injury by formation of hydroxyl radical from hydrogen peroxide. We measured Cu,Zn-SOD and Mn-SOD activities in peripheral lymphocytes of 43 newly diagnosed idiopathic Parkinson's disease (PD) cases and 62 age- and sex-matched controls free of neurodegenerative disorders. Significant excesses of both SOD forms were found among PD cases compared with controls; however, the excesses were found exclusively among FD patients treated with the monoamine oxidase inhibitor selegiline (L-deprenyl). Enzyme-linked immunosorbent assays (ELISAs) confirmed that the activity excesses were due to increased protein rather than more highly reactive enzymes in lymphocytes of PD cases. Our findings clearly indicate the importance of selegiline on measured Cu,Zn-SOD and Mn-SOD activity in peripheral lymphocytes. Characterizing a possible therapeutic value of SOD will require longitudinal assessments of SOD in relation to PD progerssion.
引用
收藏
页码:378 / 381
页数:4
相关论文
共 19 条
[11]   A HIGHLY SENSITIVE METHOD FOR DETERMINING BOTH MN-ZN AND CU-ZN SUPEROXIDE-DISMUTASE ACTIVITIES IN TISSUES AND BLOOD-CELLS [J].
NAKANO, M ;
KIMURA, H ;
HARA, M ;
KUROIWA, M ;
KATO, M ;
TOTSUNE, K ;
YOSHIKAWA, T .
ANALYTICAL BIOCHEMISTRY, 1990, 187 (02) :277-280
[12]  
POIRIER J, 1994, ANN NY ACAD SCI, V738, P116
[13]   ERYTHROCYTE ANTIOXIDANT ACTIVITY IN HUMAN PATIENTS WITH PARKINSONS-DISEASE [J].
POIRIER, J ;
BARBEAU, A .
NEUROSCIENCE LETTERS, 1987, 75 (03) :345-348
[14]  
ROSETTI ZL, 1988, BIOCHEM PHARMACOL, V37, P4573
[15]   A SELECTIVE INCREASE IN PARTICULATE SUPEROXIDE-DISMUTASE ACTIVITY IN PARKINSONIAN SUBSTANTIA NIGRA [J].
SAGGU, H ;
COOKSEY, J ;
DEXTER, D ;
WELLS, FR ;
LEES, A ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1989, 53 (03) :692-697
[16]  
SANDLER M, 1993, ADV NEUROL, V60, P238
[17]   MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSONS-DISEASE [J].
SCHAPIRA, AHV ;
COOPER, JM ;
DEXTER, D ;
CLARK, JB ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (03) :823-827
[18]   ADVANCES IN OUR UNDERSTANDING OF THE MECHANISMS OF THE NEUROTOXICITY OF MPTP AND RELATED-COMPOUNDS [J].
TIPTON, KF ;
SINGER, TP .
JOURNAL OF NEUROCHEMISTRY, 1993, 61 (04) :1191-1206
[19]   CEREBROSPINAL-FLUID LEVELS OF SUPEROXIDE DISMUTASES IN NEUROLOGICAL DISEASES DETECTED BY SENSITIVE ENZYME IMMUNOASSAYS [J].
YOSHIDA, E ;
MOKUNO, K ;
AOKI, S ;
TAKAHASHI, A ;
RIKU, S ;
MURAYAMA, T ;
YANAGI, T ;
KATO, K .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1994, 124 (01) :25-31